These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 8674154)

  • 1. A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis.
    Harman GS; Omura GA; Ryan K; Hainsworth JD; Cramer MB; Hahne WF
    Cancer Chemother Pharmacol; 1996; 38(4):323-8. PubMed ID: 8674154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.
    Audhuy B; Cappelaere P; Martin M; Cervantes A; Fabbro M; Rivière A; Khayat D; Bleiberg H; Faraldi M; Claverie N; Aranda E; Auclerc G; Audhuy B; Benhammouda A; Bleiberg H; Cals L; Cappelaere P; Cattan A; Cervantes A; Chevallier B; Conroy T; Cupissol D; De Grève J; Diaz-Rubio E; Seitz JF
    Eur J Cancer; 1996 May; 32A(5):807-13. PubMed ID: 9081358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
    Hesketh P; Navari R; Grote T; Gralla R; Hainsworth J; Kris M; Anthony L; Khojasteh A; Tapazoglou E; Benedict C; Hahne W
    J Clin Oncol; 1996 Aug; 14(8):2242-9. PubMed ID: 8708713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy.
    Chevallier B; Cappelaere P; Splinter T; Fabbro M; Wendling JL; Cals L; Catimel G; Giovannini M; Khayat D; Bastit P; Claverie N
    Support Care Cancer; 1997 Jan; 5(1):22-30. PubMed ID: 9010986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group.
    Rubenstein EB; Gralla RJ; Hainsworth JD; Hesketh PJ; Grote TH; Modiano MR; Khojasteh A; Kalman LA; Benedict CR; Hahne WF
    Cancer; 1997 Mar; 79(6):1216-24. PubMed ID: 9070501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granisetron vs dolasetron for acute chemotherapy-induced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot study.
    Tan M; Xu R; Seth R
    Curr Med Res Opin; 2004 Jun; 20(6):879-82. PubMed ID: 15200746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy.
    Yeilding A; Bertoli L; Eisenberg P; Plezia P; Modiano MR; Alberts DS; Khojasteh A; Cramer MB; Hahne WF
    Am J Clin Oncol; 1996 Dec; 19(6):619-23. PubMed ID: 8931684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group.
    Grote TH; Pineda LF; Figlin RA; Pendergrass KB; Hesketh PJ; Karlan BY; Reeves JA; Porter LL; Benedict CR; Hahne WF
    Cancer J Sci Am; 1997; 3(1):45-51. PubMed ID: 9072308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide.
    Hesketh PJ; Gandara DR; Hesketh AM; Facada A; Perez EA; Webber LM; Martin LA; Cramer MB; Hahne WF
    Support Care Cancer; 1996 Mar; 4(2):141-6. PubMed ID: 8673351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting. Pooled analysis of 14 clinical trials.
    Whitmore JB; Kris MG; Hesketh PJ; Grote TH; DuBois DM; Cramer MB; Hahne WF
    Support Care Cancer; 1998 Sep; 6(5):473-8. PubMed ID: 9773466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting.
    Fauser AA; Pizzocaro G; Schueller J; Khayat D; Wilkinson P
    Support Care Cancer; 2000 Jan; 8(1):49-54. PubMed ID: 10650898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin.
    Kris MG; Grunberg SM; Gralla RJ; Baltzer L; Zaretsky SA; Lifsey D; Tyson LB; Schmidt L; Hahne WF
    J Clin Oncol; 1994 May; 12(5):1045-9. PubMed ID: 8164028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prophylaxis of nausea and vomiting after thyroid surgery: comparison of oral and intravenous dolasetron with intravenous droperidol and placebo].
    Danner K; Becker HG; Best B; Madler C
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2001 Jul; 36(7):425-30. PubMed ID: 11496617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone.
    Kris MG; Pendergrass KB; Navari RM; Grote TH; Nelson AM; Thomas V; Ferguson BB; Allman DS; Pizzo BA; Baker TW; Fernando IJ; Chernoff SB
    J Clin Oncol; 1997 May; 15(5):2135-8. PubMed ID: 9164228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
    Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind, randomized study of two different dosage regimens of intravenous dolasetron in patients receiving high-dose cisplatin chemotherapy.
    Kasimis BS; Tapazoglou E; Schulman P; Stewart WH; Hahne WF; Cramer MB
    Cancer Invest; 1997; 15(4):304-10. PubMed ID: 9246150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous dolasetron mesilate ameliorates postoperative nausea and vomiting.
    Diemunsch P; Leeser J; Feiss P; D'Hollander A; Bradburn BG; Paxton D; Whitmore J; Panouillot P; Navé S; Brown RA; Hahne WF
    Can J Anaesth; 1997 Feb; 44(2):173-81. PubMed ID: 9043731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy.
    Coppes MJ; Lau R; Ingram LC; Wiernikowski JT; Grant R; Howard DR; Perrotta M; Barr R; Dempsey E; Greenberg ML; Leclerc JM
    Med Pediatr Oncol; 1999 Aug; 33(2):99-105. PubMed ID: 10398184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
    Eisenberg P; Figueroa-Vadillo J; Zamora R; Charu V; Hajdenberg J; Cartmell A; Macciocchi A; Grunberg S;
    Cancer; 2003 Dec; 98(11):2473-82. PubMed ID: 14635083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.